Portal de investigación
HARMONY. HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY.
Datos básicos
- NumeroConcesion:
- 116026
- Año inicial:
- 2017
- Año final:
- 2023
Documentos
- No hay documentos
Participantes
-
José Vicente Cervera Zamora
Colaborador/A
-
Maria Amparo Ibañez Company
Investigador Colaborador
-
Santiago Bonanad Boix
Colaborador/A
-
Miguel Ángel Sanz Alonso
Colaborador/A
-
Guillermo Sanz Santillana
Investigador Principal
-
Elvira Mora Castera
Licenciado
-
Maria Rosario Penades Jorda
Licenciado
-
Judith Garcia Ejome
Licenciado
-
Mireya Morote Faubel
Investigador Colaborador
-
Neus Fabregat Cabello
Licenciado
-
Cristina Abad Rodríguez
Licenciado
-
Álvaro Díaz Gonzalez
Investigador Colaborador
Grupos
-
Hemostasia, Trombosis, Arteriosclerosis y Biología vascular
Investigador Principal
Pilar Medina Badenes
-
Hematología y Hemoterapia
Investigador Principal
Javier De La Rubia Comos
Financiadores
Resultados del Proyecto
Acute Myeloid Leukemia in Adults
Versluis, J; (...); Nagler, A
Article. 10.1007/978-3-030-02278-5_69. 2019
A case of megaloblastic anemia simulating a cold autoimmune hemolytic anemia.
De La Puerta R; (...); Solves P
Article. 2020
A Lot to Learn about Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia
Editorial Material. 10.1016/j.bbmt.2017.03.011. 2017
A NEW INTRONIC MUTATION CAUSES AN ABERRANT SPLICING IN THE ANK1 GENE
Liquori, A.; (...); Cervera, J., V
Meeting Abstract. 2018
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
Martínez-Cuadrón D; (...); CETLAM and PETHEMA groups
Article. 10.1007/s00277-018-3229-5. 2018
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients
Martinez-Cuadron, D; (...); Spanish PETHEMA group
Article. 10.1016/j.leukres.2018.11.006. 2019
A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS
Oster, HS; (...); Mittelman, M
Article. 10.1182/bloodadvances.2020004055. 2021
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study
Maggioni, Giulia; (...); Della Porta, Matteo G.
Article. 10.1016/S2352-3026(22)00323-4. 2023
A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms
Liquori, A; (...); Cervera, J
Article. 10.3390/cancers13081947. 2021
A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
Kuendgen, A.; (...); Sanz, G.
Meeting Abstract. 10.1016/j.leukres.2023.107226. 2023
a2-Macroglobulin is a significant in vivo inhibitor of activated protein C and low levels of APC:a2M are associated with venous thromboembolism
Navarro S; (...); Medina P
Article. 2018
Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes
Savona, Michael R.; (...); Solary, Eric
Meeting Abstract. 10.1182/blood-2019-130722. 2019
ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS - AN ANALYSIS OF THE IWG-PM DATABASE
Pfeilstoecker, M.; (...); Greenberg, P.
Meeting Abstract. 10.1016/j.leukres.2023.107230. 2023
Adherence to prophylaxis in adult patients with severe haemophilia A
Bonanad, S; (...); Alvarez, M
Meeting Abstract. 2019
Adoptive transfer of ex-vivo expanded SARS-CoV-2-specific Cytotoxic Lymphocytes: a viable strategy for COVID-19 immunosuppressed patients?
Guerreiro M; (...); Piñana JL
Article. 10.1111/tid.13602. 2021
Adverse effects after a single moderate-volume strong-intensity strength training session in patients with severe hemophilia: feasibility and safety study
Querol-Fuentes, F; (...); Bonanad, S
Meeting Abstract. 2018
Age-related neuropathies and tubulin acetylation
Fernández-Barrera J, Correas I, Alonso MA
Editorial Material. 10.18632/aging/101432. 2018
alpha(2)-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC: alpha M-2 Levels Are Associated with Venous Thromboembolism
Martos, L; (...); Medina, P
Article. 10.1055/s-0038-1629902. 2018
Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia.
Article. 10.1002/ccr3.1206. 2017
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
de Witte, T; (...); Kröger N
Review. 10.1182/blood-2016-06724500. 2017
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
Stahl, Maximilian; (...); Zeidan, Amer M.
Letter. 10.1182/bloodadvances.2022008747. 2023
An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens
Sobas, M; (...); GATLA Cooperative Grp
Article. 10.1080/10428194.2018.1516875. 2019
An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia
Shouval, Roni; (...); Nagler, Arnon
Article. 10.1158/1078-0432.CCR-17-0489. 2017
Analysis of post Allo-HCT relapse in acute leukaemia patients, a comparative on second Allo-HCT and donor lymphocyte infusions
Orti, G; (...); Valcarcel, D
Meeting Abstract. 2017
Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions
Orti, G; (...); Valcarcel, D
Article. 10.1016/j.exphem.2018.03.002. 2018
Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype
Ibanez, M; (...); Cervera, J
Article. 10.1038/s41598-020-61589-9. 2020
ANALYSIS OF THE PREDICTIVE VALUE OF THE DIRECT ANTIGLOBULIN TEST (PAD) IN THE DIAGNOSIS OF THE NEWBORN HEMOLYTIC DISEASE (EHRN) FOR ABO INCOMPATIBILITY
Alberte, CF; (...); Alonso, MAS
Meeting Abstract. 2017
ANALYSIS OF THE USE OF MOBILE APPLICATIONS IN PATIENTS WITH HAEMOPHILIA AFTER TWO YEARS OF FOLLOW-UP
Megias Vericat, J. E.; (...); Bonanad Boix, S.
Meeting Abstract. 2019
Analysis of three salvage treatment regimens after relapsed/refractory acute myeloi leukemia (AML) (FLAG-Ida, FLAGO-IDA and PLERIFLAG)
Bergua, J; (...); Montesinos, P
Meeting Abstract. 2018
Anti-D Alloimmunization after RhD-Positive Platelet Transfusion in RhD-Negative Women under 55 Years Diagnosed with Acute Leukemia: Results of a Retrospective Study
Villalba, A; (...); Solves, P
Article. 10.1159/000488804. 2018
APPLICATION OF THE MASS SEQUENCING FOR THE STUDY OF MUTATIONS, REORDERINGS AND CHANGES IN GENE EXPRESSION IN THE HEMATOLOGICAL MYELOID NEOPLASIAS
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2018
APPROACH TO THE STUDY OF THE ALTERATIONS OF METABOLISM IN THE LMA
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2018
Assessment of Kinect V2 for elbow range of motion estimation in people with haemophilia using an angle correction model
Mateo, F; (...); Perez-Alenda, S
Article. 10.1111/hae.13744. 2019
Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin
Rodriguez-Veiga, R; (...); spanish PETHEMA group
Article. 10.1007/s00277-017-3004-z. 2017
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Bernard E; (...); Papaemmanuil E
Correction. 10.1038/s41591-021-01253-5. 2021
Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Espanol De Trasplante de Medula Osea en Nimos (GETMON) and the Grupo Espanol de Trasplante Hematopoyetico (GETH)
Gonzalez-Vicent, M; (...); Sanz, MA
Review. 10.1016/j.tmrv.2018.02.005. 2018
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
Casanova, B; (...); Coret, F
Article. 10.1007/s10072-017-2933-6. 2017
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
Diez-Campelo, M; (...); Fenaux, P
Article. 10.1111/bjh.15190. 2018
Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2018.12.027. 2019
Benefits of Ehl Factor VIII Replacement Therapy in Hemophilia: Observations on Coverage, Physical Activity and Phisiotherapy
Querol, Felipe; (...); Bonanad Boix, Santiago
Meeting Abstract. 10.1182/blood-2019-125651. 2019
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H; (...); Topp, MS
Article. 10.1056/NEJMoa1609783. 2017
Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in HematologY Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools.
Cerisoli, Francesco; (...); Hernandez Rivas, Jesus Maria
Article. 10.1016/j.jval.2022.04.1729. 2022
Case report of a trichohepatoenteric syndrome due to heterozygous compound of novel mutations in ttc37 gen
Polo, B.; (...); Cervera, J.
Meeting Abstract. 2019
CASE REPORT OF SHAAF-YANG SYNDROME WITH A DE NOVO MUTATION IN MAGEL2 GEN
Pi, G.; (...); Cervera, J.
Meeting Abstract. 2019
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
Madry, Krzysztof; (...); Smith, Alex
Article. 10.1111/bjh.18542. 2022
Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2020.12.019. 2021
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes.
Bersanelli M; (...); Della Porta MG
Article. 10.1200/JCO.20.01659. 2021
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M; (...); Zeidan AM
Article. 10.1016/j.blre.2023.101128. 2023
Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry
Lopez Cadenas, Felix; (...); Diez-Campelo, Maria
Meeting Abstract. 10.1182/blood-2021-152678. 2021
Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group
Nomdedeu, M; (...); Spanish MDS Group
Article. 10.1016/j.leukres.2017.10.011. 2017
Clinical and biological significance of Y chromosome loss in a series of 2,423 male patients with Myelodysplastic syndromes and Chronic Myelomonocytic Leukemia
Costa, D.; (...); Campo, E.
Meeting Abstract. 2018
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.
Tentori CA; (...); Della Porta MG
Article. 10.1200/JCO.23.02175. 2024
Clinical and molecular characterization by next generation sequencing of Spanish patients affected by congenital deficiencies of fibrinogen.
Moret, A; (...); Bonanad, S
Letter. 10.1016/j.thromres.2019.06.015. 2019
CLINICAL AND MOLECULAR CHARACTERIZATION BY SEQUENCING OF NEW GENERATION OF PATIENTS AFFECTED BY FIBRINOGEN CONGENITAL DEFICIENCIES
Moret, A.; (...); Bonanad, S.
Meeting Abstract. 2019
CLINICAL APPLICATION OF THE MASSIVE SEQUENCING ADDRESSED IN ACUTE MYELOBLASTIC LEUKEMIA
Garcia, ML; (...); Gonzalez, EB
Meeting Abstract. 2017
Clinical Characteristics and Transfusion Management of Patients Diagnosed of Multiple Myeloma Receiving Daratumumab: Experience of a Single Centre
Arnao, M; (...); Sanz, G
Meeting Abstract. 10.1016/j.clml.2019.09.254. 2019
Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study
Pinana, JL; (...); Navarro, D
Article. 10.1093/cid/ciy792. 2019
Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes
Riva, Elena; (...); Della Porta, Matteo G.
Meeting Abstract. 10.1182/blood-2022-166050. 2022
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
Almeida AM; (...); Pleyer L
Article. 10.3390/ijms18040837. 2017
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy
Labrador, J; (...); GATLA Grp
Article. 10.1080/10428194.2018.1522438. 2019
Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics
Alonso, CM; (...); Barragan, E
Article. 10.1016/j.jmoldx.2018.09.009. 2019
CLINICAL VALIDATION OF THE SPECIFIC POPULATION MODEL OF FACTOR VIII/FVW PLASMA USING WAPPS-HEMO
Megias Vericat, J. E.; (...); Poveda, A. J. L.
Meeting Abstract. 2019
CLINICAL-BIOLOGICAL AND PROGNOSTIC CHARACTERISTICS OF LOW RISK SMD WITHOUT RING SIDEROBLASTS AND COMPARISON WITH ITS COUNTERPART WITH RING SIDEROBLASTS
Cadenas Felix, Lopez; (...); Ferreiras David, Valcarcel
Meeting Abstract. 2021
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance
Schanz, J; (...); Haase, D
Article. 10.1002/gcc.22667. 2018
Clonal composition and its prognostic significance in patients with MDS
Schanz, J; (...); Int Working Grp Prognosis MDS
Meeting Abstract. 2018
Clonal Cytopenias and Oligoblastic Myelogenous Leukemia (myelodysplasia) Have Neoplastic, not Hyperplastic, Erythropoiesis Reply
Arenillas, L; (...); Florensa, L
Letter. 10.1200/JCO.2016.71.3941. 2017
Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes
Martinez-Losada, C; (...); Sanchez-Garcia, J
Letter. 10.3324/haematol.2018.188433. 2018
Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation
Stiff, PJ; (...); Sanz, G
Article. 10.1016/j.bbmt.2018.02.012. 2018
Collaborative model of home delivery program in haemophilia through an association of patients
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Combining gene mutation with gene expression analysis improves outcomes prediction in acute promyelocytic leukemia.
Lucena-Araujo, Antonio R.; (...); Rego, Eduardo M.
Article. 10.1182/blood.2019000239. 2019
Community acquired respiratory virus infections in adult patients undergoing umbilical cord blood transplantation.
Montoro J; (...); Piñana JL
Article. 10.1038/s41409-020-0943-0. 2020
Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections
Pinana, JL; (...); Navarro, D
Article. 10.1111/tid.12926. 2018
Comparison between Two Protocols for Platelet Transfusion in Patients Undergoing ABO Incompatible Hematopoietic Stem Cell Transplantation
Carpio, N; (...); Sanz, M
Meeting Abstract. 2018
Comparison of Clinical Characteristics and Prognosis of a Series of Patients from the Spanish Registry of MDS Diagnosed with Myelodysplastic/Myeloproliferative Neoplasms According to the 2016 Reviewed Classification of the World Health Organization
Xicoy, B; (...); Tzu, HCL
Meeting Abstract. 10.1182/blood-2018-99-111883. 2018
COMPARISON OF CLINICAL CHARACTERISTICS AND PROGNOSIS OF CHRONIC MYELOMONOCYTIC LEUKEMIA WITH AND WITHOUT AUTOINMUNE DISEASE
Moreno, AT; (...); Santillana, GS
Meeting Abstract. 2018
COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
Kuendgen, A.; (...); Sanz, G.
Meeting Abstract. 2021
Comparison of isotope pattern deconvolution and calibration curve quantification methods for the determination of estrone and 17 beta-estradiol in human serum
Pitarch-Motellon, J; (...); Cavalier, E
Article. 10.1016/j.jpba.2019.04.013. 2019
COMPARISON OF THREE PANELS OF NGS APPLICATION IN ONCOHEMATOLOGY TO DISCARD SOMATIC AND/OR GERMINAL VARIANTS
Guzman-Gimenez, C.; (...); Such, E.
Meeting Abstract. 2021
Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation
Article. 10.1111/ejh.13270. 2019
CONCORDANCE STUDY ON THE CATEGORIZATION OF NON-CANONICAL VARIANTS OF JAK2 GENE
Guzman-Gimenez, C.; (...); Such, E.
Meeting Abstract. 2021
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes.
Zeidan, Amer M.; (...); Fenaux, Pierre
Article. 10.1182/blood.2022018604. 2023
Contemporary Approach to The Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes- Recommendations from The International Consortium for MDS (icMDS).
Aakash, Fnu; (...); Loghavi, Sanam
Article. 10.1016/j.modpat.2024.100615. 2024
CO-OCCURRENCE PROFILES OF GERMLINE AND ACQUIRED VARIANTS IN MYELODYSPLASTIC SYNDROMES IN YOUNG ADULTS WITHOUT PRIOR ORGAN DYSFUNCTION
Hua, Chen-Liang Tzu; (...); Andres, Jerez
Meeting Abstract. 2021
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Martínez-Cuadrón D; (...); CETLAM and PETHEMA groups
Article. 10.1007/s00277-018-3277-x. 2018
Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients.
Chelle P; (...); Edginton A
Article. 10.1007/s10928-019-09647-2. 2019
CRISPR to fix bad blood: a new tool in basic and clinical hematology
Gonzalez-Romero, E; (...); Sanjuan-Pla, A
Review. 10.3324/haematol.2018.211359. 2019
Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1111/hae.13733. 2019
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
Eduardo Megias, Juan; (...); Iorio, Alfonso
Meeting Abstract. 10.1182/blood-2019-127946. 2019
Cryopreservation of Allogeneic Hematopoietic Progenitor Cells in The Current SARS-Cov-2 Pandemic: Experience of A Single Centre
Moreno, D; (...); Carpio, N
Meeting Abstract. 2021
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).
Bewersdorf, Jan Philipp; (...); Zeidan, Amer M.
Article. 10.1016/j.blre.2023.101072. 2023
Current management of patients with chronic myelomonocytic leukemia
Review. 10.1097/CCO.0000000000000486. 2018
CURRENT STATE OF ACUTE MYELOID LEUKEMIA IN SPAIN: RESULTS FROM A DELPHI STUDY ON EPIDEMIOLOGY, DISEASE MANAGEMENT AND UNMET NEEDS
Montesinos, P; (...); Sierra, J
Meeting Abstract. 2018
Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping.
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Article. 10.3390/cancers15113039. 2023
Challenges in Clinical Metaproteomics Highlighted by the Analysis of Acute Leukemia Patients with Gut Colonization by Multidrug-Resistant Enterobacteriaceae
Rechenberger, J; (...); Kuster, B
Article. 10.3390/proteomes7010002. 2019
CHANGES IN THE HEMATIC AND SERUM GROUP IN PATIENTS SUBJECTED TO TRANSPLANTATION OF HEMATOPOIETIC PROGENITORS WITH ABO MAYOR INCOMPATIBILITY
Balsera, MS; (...); Sanz, M. A.
Meeting Abstract. 2017
Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study
JUAN PALAU BARGUES; (...); Sanz MA
Article. 10.1080/10245332.2017.1311442. 2017
Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols.
Sobas M; (...); PETHEMA, HOVON, PALG, GATLA cooperative groups
Article. 10.1111/ejh.13346. 2020
Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide - an International Collaborative Study
Kayser, S; (...); Montesinos, P
Meeting Abstract. 10.1182/blood-2018-99-111768. 2018
CHARACTERIZATION OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA BY MEANS OF IMMUNOLOGICAL AND MOLECULAR TECHNIQUES: RESULTS OF THE GEPTT NATIONAL COLLECTION
Liquori, A.; (...); Gomez-Segui, I
Meeting Abstract. 2019
CHARACTERIZATION OF CHARACTERISTIC MORPHOLOGICAL ALTERATIONS IN PATIENTS WITH MDS/CMML AND GENE MUTATIONS OF SPLICING DIFFERENT TO SF3B1
Marco Ayala, J.; (...); Sanz, G.
Meeting Abstract. 2019
CHARACTERIZATION OF MUTATIONS ALTERING THE PROCESS OF SPLICING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
Boluda-Navarro, M.; (...); Cervera, J.
Meeting Abstract. 2018
CHARACTERIZATION OF THE GENOMIC AND TRANSCRIPTOMIC PROFILE OF THE ACUTE MYELOID LEUKEMIA (AML) SUBGROUP "CHROMATIN-SPLICEOSOME"
Alessandro, Liquori; (...); Zamora Jose, Cervera
Meeting Abstract. 2020
CHOOSING THE APPROPRIATE DENOMINATOR FOR COUNTING BM BLASTS
Arenillas, L; (...); Florensa, L
Meeting Abstract. 10.1016/S0145-2126(17)30121-2. 2017
CHROMOSOMAL ABERRATIONS IN THERAPY-RELATED MYELODYSPLASTIC SYNDROMES - RELATIONS TO PRIMARY DISEASE, THERAPY AND PROGNOSTIC SIGNIFICANCE
Nomdedeu, M; (...); Haase, D
Meeting Abstract. 10.1016/S0145-2126(17)30161-3. 2017
Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation.
Caballero JC; (...); Díez Campelo M
Article. 10.1007/s00277-019-03751-6. 2019
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.
Komrokji RS; (...); Della Porta MG
Article. 10.1016/S2352-3026(24)00251-5. 2024
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1080/17512433.2019.1573668. 2019
Detection of plasmid-mediated colistin resistance, mcr-1 gene, in Escherichia coli isolated from high-risk patients with acute leukemia in Spain
Lalaoui, R; (...); Rolain, JM
Article. 10.1016/j.jiac.2019.03.007. 2019
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.
Stojkov I; (...); Siebert U
Article. 10.1182/bloodadvances.2022008360. 2023
Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate ): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup.
Chelle P; (...); Iorio A
Article. 10.1007/s40262-019-00809-6. 2020
DEVELOPMENT OF A CELLULAR MODEL OF ACUTE MYELOID LEUKEMIA THROUGH CRISPR/CAS 9 TECHNOLOGY
Romero, EG; (...); Zamora, JVC
Meeting Abstract. 2017
Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group.
Rochau U; (...); Stauder R
Article. 10.1111/bjh.16654. 2020
DEVELOPMENT OF A MASSIVE SEQUENCING TEST FOR THE SIMULTANEOUS DETECTION OF POTENTIAL MUTATIONS AND CHROMOSOMAL ALTERATIONS IN PATIENTS WITH MYELODISPLASIC SYNDROMES
Liquori, A.; (...); Zamora, JVC
Meeting Abstract. 2017
Dexamethasone does not prevent malignant cell reintroduction in leukemia patients undergoing ovarian transplant: risk assessment of leukemic cell transmission by a xenograft model
Diaz-Garcia, C; (...); Pellicer, A
Article. 10.1093/humrep/dez115. 2019
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Döhner H; (...); Bloomfield, CD
Review. 10.1182/blood-2016-08-733196. 2017
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults Recommendations From the European Hematology Association and the European LeukemiaNet
Itzykson, R; (...); European LeukemiaNet
Article. 10.1097/HS9.0000000000000150. 2018
DIAGNOSIS OF NOONAN SYNDROME AFTER STUDY OF NGS BY ESSENTIAL THROMBOCITEMIA
Marco Ayala, J.; (...); Sanz, M. A.
Meeting Abstract. 2018
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia
Megias-Vericat, JE; (...); Spanish PETHEMA Grp
Article. 10.4084/MJHID.2019.016. 2019
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS
Miyazaki, Y; (...); Greenberg, PL
Article. 10.1016/j.leukres.2018.08.022. 2018
Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)
Santini, Valeria; (...); Zeidan, Amer M.
Meeting Abstract. 10.1182/blood-2022-160282. 2022
Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?
Article. 10.1182/bloodadvances.2019000680. 2019
Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database
Azibeiro Melchor, Raul; (...); Ossenkoppele, Gert J.
Meeting Abstract. 10.1182/blood-2021-150766. 2021
Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories
Pfeilstocker, Michael; (...); Greenberg, Peter L.
Meeting Abstract. 10.1182/blood-2022-158671. 2022
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes
Itzykson, R; (...); European MDS Registry Members
Article. 10.1182/bloodadvances.2018020495. 2018
EFFECT OF MISSENSE MUTATIONS IN THE SPLICING OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA
Morote-Faubel, M.; (...); Cervera, J.
Meeting Abstract. 2019
Effect of monitoring daily physical activity on quality of life in adult patients with haemophilic arthropathy
Perez-Alenda, Sofia; (...); Carrasco, Juan J.
Meeting Abstract. 2018
Effect of radiosynoviorthesis on the progression of arthropathy and haemarthrosis reduction in haemophilic patients
Querol-Giner, M.; (...); Querol, F.
Article. 10.1111/hae.13326. 2017
EFFECTIVENESS AND SAFETY OF THE INFUSION OF DONOR LYMPHOCYTES AFTER HAPLOIDENTICAL TRANSPLANTATION OF HEMATOPOYETIC PROGENITOR CELLS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: MULTICENTRIC RETROSPECTIVE STUDY OF THE HEMATOPETIC SPANISH TRIPASHOLE GROUP
Martin-Sanchez, Guillermo; (...); Bermudez, Aranzazu
Meeting Abstract. 2020
Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group
Pleyer, Lisa; (...); Greil, Richard
Meeting Abstract. 10.1182/blood-2019-123941. 2019
eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice
Bonanad, S; (...); Megias-Vericat, JE
Meeting Abstract. 2018
Electromyographic and Safety Comparisons of Common Lower Limb Rehabilitation Exercises for People With Hemophilia.
Calatayud J; (...); Casaña J
Article. 10.1093/ptj/pzz146. 2020
Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Meeting Abstract. 10.1182/blood-2023-180691. 2023
Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)
Calvo, X; (...); Florensa, L
Article. 10.1002/ajh.24732. 2017
Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)
Segui, Ines Gomez; (...); Garma, Julio Del Rio
Meeting Abstract. 2024
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome
Garelius, HKG; (...); Hellström-Lindberg E
Article. 10.1111/joim.12579. 2017
Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies
Paviglianiti, A; (...); Rocha, V
Article. 10.1111/bjh.14962. 2017
Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial
Lopez Cadenas, Felix; (...); Diez-Campelo, Maria
Meeting Abstract. 10.1182/blood-2022-168718. 2022
EVALUATION OF THE EFFECT OF DIFFERENT LIGANDS OF TLRS IN THE PROLIFERATION AND DIFFERENTIATION OF ACUTE MYELOID LEUKEMIA CELLS
Fernandez, JG; (...); Ribate, EV
Meeting Abstract. 2017
EVALUATION OF THE MUTATION OF FLT3 IN ACUTE MYELOID LEUKAEMIA: RESULTS OF THE DELPHI QUESTIONNAIRE OF THE SPANISH GROUP
Gomez-Casares, M. T.; (...); Sierra, J.
Meeting Abstract. 2019
Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death
Madry, K; (...); Smith, A
Meeting Abstract. 10.1182/blood-2018-99-115928. 2018
Excess mortality in the myelodysplastic syndromes
Nomdedeu, M; (...); Spanish MDS Group
Article. 10.1002/ajh.24606. 2017
Experience of Home Delivery Program in Haemophilia Through an Association of Patients
Megias Vericat, J. E.; (...); Bonanad Boix, S.
Meeting Abstract. 2017
EXPLOITING CUTTING-EDGE TECHNOLOGIES TO ANALYZE LOSS OF HLA IN A GLOBAL MULTICENTRIC COHORT OF POST-TRANSPLANTATION RELAPSES: PRELIMINARY RESULTS FROM THE HLALOSS COLLABORATIVE STUDY
Vago, Luca; (...); Fleischhauer, Katharina
Meeting Abstract. 2018
Exploiting Cutting-Edge Technologies to Analyze Loss of HLA in a Global Multicentric Cohort of Post-Transplantation Relapses: Preliminary Results from the HLALOSS Collaborative Study
Vago, Luca; (...); Fleischhauer, Katharina
Meeting Abstract. 2018
EXPLOITING CUTTING-EDGE TECHNOLOGIES TO ANALYZE LOSS OF HLA IN A MULTICENTRIC COHORT OF POST-TRANSPLANTATION RELAPSES: RESULTS FROM THE HLALOSS GLOBAL COLLABORATIVE STUDY
Vago, L.; (...); Fleischhauer, K.
Meeting Abstract. 2018
Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation
Solves P; (...); Carpio N
Article. 10.1007/s00277-017-3168-6. 2018
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
Hernandez-Boluda, JC; (...); GELMC
Article. 10.1038/s41408-018-0125-0. 2018
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
Zeidan, Amer M.; (...); Santini, Valeria
Article. 10.1038/s41375-022-01724-9. 2022
Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia
Pallarès V; (...); Casanova, I
Article. 10.3390/cancers10110436. 2018
FREQUENCY AND CLINICAL IMPACT OF CDKN2A/B GENE LOCUS IN AN ADULT T-ALL COHORT OF PATIENTS ENROLLED IN THE SPANISH PETHEMA GROUP PROTOCOLS
Genesca, E; (...); Ribera, JM
Meeting Abstract. 2017
FUNCTIONAL CLASSIFICATION OF DEEP INTRONIC VARIANTS IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA
Liquori, A.; (...); Cervera Zamora, J.
Meeting Abstract. 2019
FUNCTIONAL RECLASSIFICATION THROUGH MINIGENE TESTS OF MISSENSE VARIANTS WITH EFFECT ON SPLICING IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
Morote-Faubel, Mireya; (...); Cervera, Jose
Meeting Abstract. 2020
FUNCTIONAL STUDY OF SILENCED HMGCR GENE IN CELL LINES OF ACUTE MYELOID LEUKEMIA PATIENTS
De Matteo, B; (...); Zamora, JVC
Meeting Abstract. 2017
GAH SCALE PREDICTS TREATMENT TOLERABILITY IN OLDER PATIENTS (> 65 YEARS) DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES
Bonanad, S; (...); de la Rubia, J
Meeting Abstract. 2017
Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
D'Amico, Saverio; (...); Della Porta, Matteo Giovanni
Meeting Abstract. 10.1182/blood-2024-209541. 2024
GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
Bernard, E.; (...); Papaemmanuil, E.
Meeting Abstract. 10.1016/j.leukres.2023.107146. 2023
Genomic characterization of Citrobacter freundii strains coproducing OXA-48 and VIM-1 carbapenemase enzymes isolated in leukemic patient in Spain
Lalaoui, R; (...); Rolain, JM
Article. 10.1186/s13756-019-0630-3. 2019
Germline and Acquired Genetic Variants in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction
Chen-Liang, TH; (...); Jerez, A
Meeting Abstract. 10.1182/blood-2018-99-116045. 2018
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial.
Roboz GJ; (...); Döhner H
Article. 10.1182/bloodadvances.2023012062. 2024
HaemoPREF: Further evaluation of patient perception and preference for treatment in a real world setting
Bonanad, S; (...); Brohan, E
Article. 10.1111/hae.13321. 2017
Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation
Sobas, Marta; (...); Maria Hernandez-Rivas, Jesus
Meeting Abstract. 10.1182/blood-2021-149521. 2021
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study
Stauder, R; (...); de Witte, T
Article. 10.1038/s41375-018-0089-x. 2018
HEALTH-RELATEDQUALITYOF LIFE IS SUBSTANTIALLY IMPAIRED IN LOWER-RISK MDS WHEN COMPARED WITH REFERENCE POPULATIONS AND SIGNIFICANTLY AFFECTS OVERALL SURVIVAL
Stauder, R; (...); De Witte, T
Meeting Abstract. 10.1016/S0145-2126(17)30135-2. 2017
Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China
Huang XJ; (...); Issaragrisil S
Article. 10.18632/oncotarget.15655. 2017
Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT.
Ruggeri A; (...); Nagler A
Article. 10.1038/s41409-019-0582-5. 2019
HemoKinect: A Microsoft Kinect V2 Based Exergaming Software to Supervise Physical Exercise of Patients with Hemophilia
Mateo, F; (...); Perez-Alenda, S
Article. 10.3390/s18082439. 2018
Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology
Bastida, JM; (...); Diez-Campelo, M
Article. 10.1111/ijlh.12933. 2019
High heterogeneity of multidrug-resistant Enterobacteriaceae fecal levels in hospitalized patients is partially driven by intravenous beta-lactams.
Djukovic A; (...); Ubeda C
Article. 10.1128/AAC.01415-19. 2020
IDENTIFICATION OF 58 MUTATIONS (26 NEW) IN 94 OF 109 BEING TESTED WITH PROTEIN DEFICIENCY C. SETH WORKING GROUP
Fernandez-Pardo, A.; (...); Navarro, S.
Meeting Abstract. 2019
Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C Deficiency
Martos, L; (...); Spanish Soc Thrombosis Haemostasis
Article. 10.1055/s-0039-1692440. 2019
IDENTIFICATION OF A PROFILE OF CLASSES OF CIRCULATING LIPIDS ASSOCIATED WITH THE VENOUS THROMBOEMBOLISM
Fernandez-Pardo, A.; (...); Navarro, S.
Meeting Abstract. 2019
Imiquimod inhibits growth and induces differentiation of myeloid leukemia cell lines
Villamon, E; (...); Gil, ML
Article. 10.1186/s12935-018-0515-1. 2018
Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.
Article. 10.1007/s00277-024-05758-0. 2024
Immune Reconstitution Profiling Suggests Antiviral Protection After Transplantation with Omidubicel: a Phase 3 Substudy.
Szabolcs, Paul; (...); Horwitz, Mitchell E.
Article. 10.1016/j.jtct.2023.04.018. 2023
Immune Tolerance Induction in A Patient with Severe Haemophilia A and Factor VIII Inhibitors
Freiria Alberte, C.; (...); Haya Guaita, S.
Meeting Abstract. 2017
Immunohaematological events related to changes in haematic and seric ABO group in patients undergoing haematopoietic stem cell transplantation with major ABO mismatch.
Santiago, M; (...); Solves, P
Letter. 10.1111/tme.12538. 2019
Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2016.1231405. 2017
IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)
Ibanez, Mariam; (...); Sanz, Guillermo
Meeting Abstract. 2020
Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation
Cunha R; (...); Eurocord, Cord Blood Committee Cellular Therapy–Immunobiology Working Party of t
Article. 10.1182/blood-2016-06-722249. 2017
Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study
Matteuzzi, Tommaso; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2021-152215. 2021
Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party
Rubio, MT; (...); Nagler, A
Article. 10.1186/s13045-016-0389-4. 2017
Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1038/tpj.2017.19. 2018
Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1097/FPC.0000000000000286. 2017
Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia.
Döhner K; (...); Bloomfield CD
Article. 10.1182/blood.2019002697. 2020
Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients.
de Swart L; (...); EUMDS Registry Participants
Article. 10.3324/haematol.2018.212217. 2020
IMPACT OF RED BLOOD CELL TRANSFUSIONS ON SURVIVAL IN LOWER-RISK MDS PATIENTS INCLUDED IN THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY
de Swart, L; (...); de Witte, T
Meeting Abstract. 10.1016/S0145-2126(17)30393-4. 2017
IMPACT OF THE TREATMENT OF THE PURE APLASIA OF THE RED SERIES; EXPERIENCE IN A CENTER
Marco, Ayala Javier; (...); Solves, Alcaina Pilar
Meeting Abstract. 2020
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.
Hoeks M; (...); EUMDS Registry Participants
Article. 10.3324/haematol.2018.212332. 2020
IMPLEMENTATION OF MASSIVE SEQUENCING TECHNOLOGIES TO THE DETECTION OF MUTATIONS IN THE ABL KINASE DOMAIN OF BCR-ABL REORDERING
Simarro, CS; (...); Gonzalez, EB
Meeting Abstract. 2017
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
Bernard, Elsa; (...); Elias, Harold K
Article. 10.1038/s41591-021-01367-w. 2021
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Bernard, E; (...); Papaemmanuil, E
Article. 10.1038/s41591-020-1008-z. 2020
IN VIVO MODELS FOR THE FUNCTIONAL STUDY OF CO-OCCURRING GENETIC AND EPIGENETIC MUTATIONS IN MYELODYSPLASTIC SYNDROMES
Martinez-Valiente, C.; (...); Sanjuan-Pla, A.
Meeting Abstract. 2018
IN VIVO MODELS TO STUDY THE COOPERATION BETWEEN SPLICING AND DNA METHYLATION IN MYELODYSPLASTIC SYNDROMES
Martinez-Valiente, Cristina; (...); Sanjuan-Pla, Alejandra
Meeting Abstract. 2020
Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
Rodríguez-Veiga R; (...); Sanz GF
Article. 10.1007/s00277-019-03744-5. 2019
Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.
Castillo MI; (...); Díaz TM
Article. 10.1002/cam4.6300. 2023
Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study
Vago, L; (...); Fleischhauer, K
Meeting Abstract. 10.1182/blood-2018-99-112142. 2018
Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
Sirenko, Maria; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2022-162397. 2022
Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients
Pinana, JL; (...); Navarro, D
Article. 10.1111/tid.13158. 2019
INCREASED LEVELS OF FREE CIRCULATING DNA AND DNASE 1 ACTIVITY IN PLASMA IS ASSOCIATED WITH AN INCREASED RISK OF VENOUS THROMBOEMBOLISM
Oto, J.; (...); Medina, P.
Meeting Abstract. 2019
Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Vericat, JEM; (...); Bonanad, S
Meeting Abstract. 2018
Infections of the Central Nervous System after Untelated Donor Umbilical Cord Blood Transplantation or Human teukocyte Antigen-Matched Sibling Transplantation
Balaguer Rosello A; (...); Sanz, J
Article. 10.1016/j.bbmt.2016.10.005. 2017
INFECTIONS OF THE CENTRAL NERVOUS SYSTEM IN THE ALOGENIC TRANSPLANTATION OF HEMATOPOYETIC PROGENITORS
Balaguer Rosello, A.; (...); Sanz Caballer, J.
Meeting Abstract. 2018
Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2017.1323267. 2017
IN-SILICO AND IN VITRO STUDY OF MUTATIONS THAT ALTER THE SPLICING PROCESS IN PATIENTS WITH MYELODISPLASIC SYNDROMES
Boluda-Navarro, M.; (...); Cervera, J.
Meeting Abstract. 2019
Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen
Montoro, J; (...); Pinana, JL
Article. 10.1111/ejh.13202. 2019
INVASIVE FUNGAL INFECTION IN ADULT PATIENTS SUBMITTED TO UMBILICAL CORD BLOOD TRANSPLANTATION
Montoro, J.; (...); Pinana, J. L.
Meeting Abstract. 2018
Investigation of HLA loss relapse after allogeneic stem cell transplantation in a global multicentric cohort (HLALOSS Consortium)
Fleischhauer, K; (...); Vago, L
Meeting Abstract. 2018
Isohaemagglutinin production after minor ABO incompatible umbilical cord blood transplantation
Letter. 10.1111/tme.12386. 2017
Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score.
Jiménez-Yuste V; (...); Kim HK
Article. 10.1111/hae.13628. 2019
JUVENILE MYELOMONOCITIC LEUKEMIA IN PATIENTS WITH NOONAN SYNDROME AND NOONAN-LIKE SYNDROMES: EXPERIENCE OF THE SPANISH YOUTH MYELOMONOCITIC LEUKEMIA REGISTRATION
Arques Martinez, L.; (...); Catala Temprano, A.
Meeting Abstract. 2019
LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors.
Cruz, David; (...); Gallardo, David
Article. 10.3389/fimmu.2023.1066393. 2023
Liquid chromatography-tandem mass spectrometry for monitoring vitamin D hydroxymetabolites in human aqueous humor
Fabregat-Cabello, N; (...); Cavalier, E
Article. 10.1039/c9ay01896d. 2019
Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers
Jose Gonzalez-Lopez, Tomas; (...); Sanz, Miguel A.
Meeting Abstract. 10.1182/blood-2019-129274. 2019
Long Term Survival Analysis of Multiple Myeloma Patients Receiving Induction Therapy plus Autologous STEM CELL Trasplantation, Comparing Velcade-Dexametasone to Alkylating Polichemotherapy As Induction Therapy
Caceres, S; (...); Burgues, JMMB
Meeting Abstract. 10.1182/blood-2018-99-116924. 2018
Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice.
Gomez, E; (...); Fernandez-Rodriguez, C M
Article. 10.1111/apt.18004. 2024
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy
Martínez-Cuadrón D; (...); Sanz MA
Article. 10.1038/leu.2017.178. 2018
Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation
de Koning, Coco; (...); Nierkens, Stefan
Article. 10.1038/s41409-021-01417-4. 2021
LYMPHOPENIA IS HIGHLY PREVALENT IN MDS AND PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR IPSS-R VERY-LOW AND LOW-RISK PATIENTS. AN ANALYSIS FROM THE EU-MDS REGISTRY
Silzle, T.; (...); Smith, A.
Meeting Abstract. 2021
Lymphopenia is highly prevalent in MDS and provides prognostic information for IPSS-R (very)-low-risk patients. An analysis from the EU-MDS registry
Silzle, T.; (...); Smith, A.
Meeting Abstract. 2021
Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance
Hernandez Sanchez, Alberto; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2022-167138. 2022
Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform
Hernandez Sanchez, Alberto; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2023-183029. 2023
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
Sanz, MA; (...); Lo-Coco, F
Article. 10.1182/blood-2019-01-894980. 2019
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.
Onida F; (...); Pleyer L
Article. 10.1182/blood.2023023476. 2024
Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset
Bowen, David; (...); de Witte, Theo M.
Meeting Abstract. 10.1182/blood-2021-150322. 2021
Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases
Smoljanovic, Inga Mandac; (...); Bowen, David
Meeting Abstract. 10.1182/blood-2022-167716. 2022
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.
Buske C; (...); Passamonti F
Article. 10.1016/j.esmoop.2022.100403. 2022
MASS SEQUENCING DIRECTED TO THE STUDY OF REARRANGEMENTS AND CHANGES IN GENIC EXPRESSION IN ACUTE MYELOID LEUKEMIA
Sargas Simarro, C.; (...); Barragan Gonzalez, E.
Meeting Abstract. 2019
MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination
Oster, HS; (...); Mittelman, M
Meeting Abstract. 10.1182/blood-2018-99-111838. 2018
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, RM; (...); Döhner H
Article. 10.1056/NEJMoa1614359. 2017
MODELING OF IDH2 GENE MUTATIONS IN THE CAENORHABDITIS ELEGANS ORGANISM. DEVELOPMENT OF A NEW STUDY MODEL
Gonzalez-Romero, E.; (...); Cervera-Zamora, J.
Meeting Abstract. 2021
Moderate and severe haemophilia in Spain: An epidemiological update
Aznar, JA; (...); Lopez, MF
Letter. 10.1111/hae.13462. 2018
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Sirenko, Maria; (...); Papaemmanuil, Elli
Article. 10.1182/blood.2023023723. 2024
Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients
Borràs N; (...); Corrales, I
Article. 10.3324/haematol.2017.168765. 2017
MOLECULAR CHARACTERIZATION OF CELLULAR MODELS OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BY MASS SEQUENCING
Navarro, MB; (...); Cervera, J
Meeting Abstract. 2017
MOLECULAR CHARACTERIZATION OF PATIENTS WITH HEREDITARY MYELOID NEOPLASIAS THROUGH MASS SEQUENCING
Pardo-Lorente, N.; (...); Cervera, J.
Meeting Abstract. 2018
MOLECULAR CHARACTERIZATION OF VARIANTS THAT ALTER SPLICING (VAS) IN PATIENTS WITH MYELODYSPLASIC SYNDROMES
Boluda-Navarro, M.; (...); Cervera, J.
Meeting Abstract. 2020
Molecular remission as a therapeutic objective in acute promyelocytic leukemia
Cicconi, L; (...); Lo-Coco, F
Review. 10.1038/s41375-018-0219-5. 2018
Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications
Bernard, Elsa; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2023-186863. 2023
Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications.
Bernard, Elsa; (...); Papaemmanuil, Elli
Article. 10.1182/blood.2023023727. 2024
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.
Lin, Chenyu; (...); Horwitz, Mitchell E.
Article. 10.1016/j.jtct.2023.01.031. 2023
Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group
Ramos, F; (...); Spanish Group for Myelodysplastic Syndromes (GESMD)
Article. 10.1002/ajh.24813. 2017
MUTATIONAL PROFILE IN PATIENTS DIAGNOSED WITH LOW-RISK SMD WITHOUT THE RINGED SIDEROBLASTS
Abaigar, M; (...); Campelo, MD
Meeting Abstract. 2018
Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
Cedena, MT; (...); Martinez-Lopez, J
Article. 10.18632/oncotarget.22157. 2017
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
Martin, I; (...); Tormo, M
Article. 10.1111/bjh.17675. 2021
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fenaux, P; (...); ESMO Guidelines Comm
Article. 10.1016/j.annonc.2020.11.002. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients
Pallares, V; (...); Mangues, R
Article. 10.18632/oncotarget.18537. 2017
New mutations found by Next-Generation Sequencing screening of Spanish patients with Nemaline Myopathy
Moreau-Le Lan, S; (...); Pedrola, L
Article. 10.1371/journal.pone.0207296. 2018
Next generation sequencing in bleeding disorders: two novel variants in the F5 gene (Valencia-1 and Valencia-2) associated with mild factor V deficiency.
Moret, A; (...); Bonanad, S
Article. 10.1007/s11239-019-01911-z. 2019
Nicord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/II Trial
Horwitz, ME; (...); Sanz, G
Meeting Abstract. 10.1016/j.bbmt.2017.12.628. 2018
Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation
Balaguer-Rosello, A; (...); Sanz, Jaime
Article. 10.1016/j.bbmt.2019.05.024. 2019
Non-infectious neurologic complications after allogeneic hematopoietic stem cell transplantation (ALLO-HSCT)
Balaguer Rosello, Aitana; (...); Sanz, Jaime
Meeting Abstract. 2019
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective.
De Witte T; (...); Smith A
Article. 10.3324/haematol.2020.266817. 2020
Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies studies and correlation with flt3 mutations and polyunsaturated fatty acid metabolism.
Mazzarella L; (...); Pelicci PG
Article. 10.3324/haematol.2019.223925. 2020
OBSERVATIONAL CLINICAL TRIAL FOR THE VALIDATION OF A TEST OF PRECISION MEDICINE IN ACUTE MYELOID LEUKEMIA
Montesinos, P.; (...); Sanz, M.
Meeting Abstract. 2017
Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.
Horwitz, ME; (...); Sanz, G
Article. 10.1182/blood.2021011719. 2021
Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice
Bonanad, S; (...); Poveda, JL
Meeting Abstract. 2018
OPTIMIZATION OF THE EFFICIENCY OF GENETIC EDITING OF HEMAPOYETIC PROGENITOR CELLS USING CRISPR/CAS9 RIBONUCLEOPROTEINS
Martinez-Valiente, C.; (...); Sanjuan-Pla, A.
Meeting Abstract. 2019
Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience.
Sobas M; (...); Giebel S
Article. 10.1016/j.clml.2019.09.616. 2020
Outcome of Acute Myeloid Leukemia with Inv(3)(Q21q26.2)/ T(3;3)(Q21;Q26.2). Experience of the Spanish PETHEMA and CETLAM Groups
Sitges, M; (...); CETLAM Cooperative Grp
Meeting Abstract. 2019
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents
Park, Sophie; (...); Fenaux, Pierre
Letter. 10.1016/j.leukres.2020.106472. 2020
OUTCOME OF LOWER-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITHOUT 5Q DELETION AFTER FAILURE OF ERYTHROPOIESIS STIMULATING AGENTS
Park, S; (...); Fenaux, P
Meeting Abstract. 10.1016/S0145-2126(17)30162-5. 2017
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents
Park S; (...); Fenaux P
Article. 10.1200/JCO.2016.71.3271. 2017
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.
Caballero, Juan Carlos; (...); Diez Campelo, Maria
Article. 10.1177/20406207231218157. 2024
Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients
Ibanez, Mariam; (...); Luna I
Article. 10.3390/diagnostics12040953. 2022
PAN-STAKEHOLDER CORE OUTCOME SET (COS) DEFINITION FOR HEMATOLOGICAL MALIGNANCIES IN THE FRAMEWORK OF THE EU PROJECT, HARMONY: THE HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINE OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY
Lang, K.; (...); Bullinger, L.
Meeting Abstract. 2023
Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects
Lang, Katharina M.; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2022-157549. 2022
Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance
Lang, Katharina M.; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2021-145002. 2021
Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia.
Sanz J; (...); Piñana JL
Article. 10.1016/j.bbmt.2019.08.020. 2020
PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines.
González-Romero E; (...); Vázquez-Manrique RP
Article. 10.3390/cancers15174263. 2023
Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.2174/1389200218666171101124931. 2018
Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) - Preliminary Blinded Analysis of the European Sintra-REV Trial
Cadenas, FL; (...); Diez-Campelo, M
Meeting Abstract. 10.1182/blood-2018-99-119430. 2018
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Roboz, Gail J.; (...); Wei, Andrew H.
Letter. 10.1080/10428194.2021.2012667. 2022
Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide
Horwitz, ME; (...); Sanz, G
Article. 10.1200/JCO.18.00053. 2019
Physical Activity In Haemophilia: Hemorrhagic Risk And Factor Levels (myPKFiT)
Querol-Fuentes, F; (...); Bonanad, S
Meeting Abstract. 2017
Physical Activity Monitoring and Acceptance of a Commercial Activity Tracker in Adult Patients with Haemophilia.
Carrasco JJ; (...); Querol F
Article. 10.3390/ijerph16203851. 2019
Pilot evaluation of home delivery programme in haemophilia
Megias-Vericat, JE; (...); Poveda-Andres, JL
Article. 10.1111/jcpt.12718. 2018
Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
Article. 10.1080/10428194.2018.1474462. 2019
Practical guide to emergency treatment of thrombotic microangiopathy
Romero S; (...); Grupo de Microangiopatía Trombótica del Hospital Universitario y Politécnico La
Editorial Material. 10.1016/j.medcli.2018.01.013. 2018
Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments
Ballesteros, J; (...); Montesinos, P
Meeting Abstract. 10.1182/blood-2018-99-115849. 2018
Predictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A real-world report from a single centre, mixed retrospective-prospective long-term study
Haya, S; (...); Casana, P
Letter. 10.1111/hae.13660. 2019
Predictive models of treatment benefit in patients with autoimmune hepatitis and decompensated cirrhosis at diagnosis
Arvaniti, Pinelopi; (...); Carlota Londono, Maria
Meeting Abstract. 2023
Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy
Abla, O; (...); Sanz, MA
Article. 10.1007/s00277-017-3042-6. 2017
PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY OF SINTRA-REV CLINICAL TRIAL, LENALIDOMIDE VS PLACEBO PHASE 3 STUDY IN LOW/INT-1 MDS PATIENTS WITH DEL(5Q) AND TRANSFUSION INDEPENDENCY
Cadenas, FL; (...); Diez-Campelo, M
Meeting Abstract. 2017
Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study
Kanda, J; (...); Gluckman, E
Meeting Abstract. 2018
Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study.
Kanda J; (...); Gluckman E
Article. 10.1038/s41375-019-0534-5. 2020
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS
de Swart, L; (...); de Witte, T
Article. 10.1016/j.leukres.2018.01.022. 2018
Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts
Martin, I; (...); Sanz, G
Article. 10.1038/s41408-017-0016-9. 2017
Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603)
Rucker, FG; (...); Dohner, K
Meeting Abstract. 10.1182/blood-2018-99-116149. 2018
PROGNOSTIC VALUE OF EARLY DROP IN PLATELETS IN LOWER-RISK MDS. A SUB-STUDY FROM THE EUROPEAN LEUKEMIANET LOWER-RISK MDS (EUMDS) REGISTRY
Itzykson, R; (...); de Witte, T
Meeting Abstract. 10.1016/S0145-2126(17)30132-7. 2017
Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies.
Sanz J; (...); Piñana JL
Article. 10.1016/j.bbmt.2019.10.014. 2020
Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia
Pinana, JL; (...); Navarro, D
Article. 10.1016/j.jinf.2019.02.009. 2019
Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.
Marco-Ayala J; (...); Solves P
Review. 10.1038/s41409-020-01124-6. 2021
qMetforminintreatment Overcomes AT-Resistance in Acute Promyelocytic Leukemia Foxo3A Expression
Pereira-Martins, DA; (...); Rego, EM
Meeting Abstract. 10.1182/blood-2018-99-115068. 2018
Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker
Perez-Alenda, S; (...); Querol, F
Letter. 10.1111/hae.13388. 2018
Radiosynoviorthesis in the Treatment of Recurrent Hemarthrosis in Patients with Haemophilia: Experience in a Single Center
Querol-Fuentes, F; (...); Bonanad, S
Meeting Abstract. 2017
Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/ Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis
Garcia-Manero, Guillermo; (...); Yacoub, Abdulraheem
Meeting Abstract. 2023
RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
Garcia-Manero, G.; (...); Yacoub, A.
Meeting Abstract. 10.1016/j.leukres.2023.107270. 2023
Rapid and Robust CD4+and CD8+T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation
Boelens, JJ; (...); Nierkens, S
Meeting Abstract. 10.1182/blood-2018-99-116700. 2018
Rapid and Robust CD4+and CD8+T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation
de Koning, Coco; (...); Boelens, Jaap-Jan
Meeting Abstract. 2019
Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy
Voso, MT; (...); Lo-Coco, F
Meeting Abstract. 10.1182/blood-2018-99-114318. 2018
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA plus )
Falantes, J; (...); European ALMA?+?Investigators
Article. 10.1080/10428194.2017.1365854. 2018
Real life outcomes of patients aged =75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.
Salamero O; (...); PETHEMA and PALG Groups
Article. 10.1080/10428194.2019.1607327. 2019
Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
Sauta, Elisabetta; (...); Della Porta, Matteo G.
Meeting Abstract. 10.1182/blood-2022-163634. 2022
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Sauta, Elisabetta; (...); Della Porta, Matteo Giovanni
Article. 10.1200/JCO.22.01784. 2023
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.
Hernandez-Sanchez, Alberto; (...); Bullinger, Lars
Article. 10.1038/s41375-024-02333-4. 2024
Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database
Hernandez Sanchez, Alberto; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2022-167480. 2022
Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015
Gonzalez, J; (...); Cohort Spanish HIV Res Network Co
Article. 10.1016/j.eimc.2019.02.007. 2019
Remote monitorization of physical exercises for patients with hemophilia using kinect V2
Perez-Alenda, S; (...); Querol-Fuentes, F
Meeting Abstract. 2018
REMOVAL OF GERMINAL LINE MUTATIONS IN PATIENTS WITH MDS AND AML: WHO SHOULD BE PERFORMED?
Santiago, Marta; (...); Cervera, Jose
Meeting Abstract. 2020
RESPONSE TO AZACITIDINE IN A SERIES OF 94 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA FROM THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROMES
Triguero, A; (...); Sanz, G
Meeting Abstract. 10.1016/S0145-2126(17)30232-1. 2017
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria*
Triguero, A.; (...); Sanz, G.
Article. 10.1016/j.leukres.2022.106836. 2022
Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)
Roboz, Gail J.; (...); Dohner, Hartmut
Meeting Abstract. 10.1182/blood-2021-147769. 2021
Results of two protocols for platelet transfusion in patients undergoing abo incompatible hematopoietic stem cell transplantation
Letter. 10.1016/j.transci.2019.02.002. 2019
Revealing the mutational landscape of acute promyelocytic leukemia
Editorial Material. 10.21037/tcr.2017.02.47. 2017
Risk of decompensated cirrhosis in patients with primary biliary cholangitis under first, second and third-line therapies
Lucena, Ana; (...); Ampuero, Javier
Meeting Abstract. 2023
RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib
Such, E; (...); Cervera, J
Article. 10.1159/000497348. 2019
Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial
Paiva, B; (...); Montesinos, P
Meeting Abstract. 10.1182/blood-2018-99-113299. 2018
Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project
Perez-Rodriguez, A; (...); Lopez-Fernandez, MF
Article. 10.1371/journal.pone.0197876. 2018
Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
Chelle, P; (...); Edginton, A
Meeting Abstract. 2018
Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients.
Chelle P; (...); Edginton A
Article. 10.1007/s10928-019-09637-4. 2019
Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program
Zeidan, Amer M.; (...); Garcia-Manero, Guillermo
Meeting Abstract. 10.1182/blood-2021-145626. 2021
Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1007/s00277-018-3304-y. 2018
Secondary and Therapy-Related Acute Promyelocytic Leukemia. Experience of the PETHEMA Registry
Montesinos, P; (...); GATLA Cooperative Grp
Meeting Abstract. 2017
Signal transducer and activator of transcription 3 (STAT3) phosphorylation regulates thromboxane A 2 receptor activity in human platelets.
Latorre AM; (...); Moscardó A
Letter. 10.1111/bjh.16309. 2020
Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT
Baron, F; (...); Nagler, A
Article. 10.1186/s13045-017-0497-9. 2017
Single umbilical cord blood with or without CD34(+) cells from a third-party donor in adults with leukemia.
Sanz, J; (...); Grp Espanol Trasplante
Article. 10.1182/bloodadvances.2017006999. 2017
SINTRA-REV CLINICAL TRIAL: PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY AT WEEK 12 OF TREATMENT IN MDS DEL(5Q) AND TRANSFUSION INDEPENDENCE
Cadenas, FL; (...); Diez-Campelo, M
Meeting Abstract. 2017
SJOGREN-LARSSON SYNDROME IN TWO SISTERS WITH AN INTRONIC VARIANT OF ALDH3A2 GENE: CLINICAL FINDINGS
Fernandez, F.; (...); Cervera, J.
Meeting Abstract. 2019
Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia
Weinhauser, I; (...); Rego, EM
Meeting Abstract. 10.1182/blood-2018-99-115370. 2018
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Palomo L; (...); Such E
Article. 10.1111/bjh.16175. 2020
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453)+azacitidine in higher risk MDS and CMML-2.
Zeidan AM; (...); Santini V
Article. 10.2217/fon-2022-1237. 2023
STUDY OF PRE-EXISTING MUTATIONS IN HEMATOPOYETIC CELLS OF THE BONE MEDULA IN PATIENTS WITH MYELOID NEOPLASIAS RELATED TO THERAPY
Ibanez, M; (...); Sanz, G
Meeting Abstract. 2017
STUDY OF THE CELL POPULATIONS INFUSED IN THE TRANSPLANT ALOGENICO OF BROTHER HLA-IDENTICAL
Villalba, A.; (...); Sanz, M. A.
Meeting Abstract. 2017
STUDY OF TRANSCRIPTIONAL DIFFERENCES BETWEEN THE IDH2 R140 AND R172 MUTATIONS BY MEANS OF MODELING IN THE ORGANISM CAENORHABDITIS ELEGANS
Gonzalez, Romero Elisa; (...); Cervera, Jose Vicente
Meeting Abstract. 2020
SUSPENSION OF TREATMENT WITH BCR-ABL INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE
Galan, IP; (...); Boluda, JCH
Meeting Abstract. 2017
The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation.
Piñana J; (...); Sanz J
Article. 10.1016/j.jinf.2019.12.022. 2020
The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS
Xicoy, Blanca; (...); Sanz, Guillermo
Letter. 10.1016/j.leukres.2018.05.003. 2018
The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey.
Piñana JL; (...); Navarro D
Article. 10.1038/s41409-019-0698-7. 2020
The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia
Lange, AP; (...); Rego, EM
Letter. 10.1111/bjh.14490. 2018
The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations.
Kanda, Junya; (...); Gluckman, Eliane
Article. 10.1038/s41409-021-01479-4. 2022
The Impact of GVHD on Outcomes After Adult Single Cord Blood Transplantation In European And Japanese Populations: The EUROCORD/ALWP EBMT And JSHCT/JDCHCT Collaborative Study
Kanda, J; (...); Gluckman, E
Meeting Abstract. 2021
The impact of progressive resistance training on physical function and quality of life in patients with haemophilia
Carrasco, JJ; (...); Querol-Fuentes, F
Meeting Abstract. 2019
The modular network structure of the mutational landscape of Acute Myeloid Leukemia
Ibanez, M; (...); Cervera, J
Article. 10.1371/journal.pone.0202926. 2018
Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS
Kuendgen, A; (...); Sanz, G
Meeting Abstract. 10.1182/blood-2018-99-118215. 2018
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
Kuendgen A; (...); Sanz G
Article. 10.1038/s41375-020-0917-7. 2020
Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain
Boluda, B; (...); Montesinos, P
Article. 10.1007/s41669-018-0098-8. 2019
Tolerability of knee and ankle exercises with machines and elastic resistance in patients with severe hemophilia
Perez-Alenda, S; (...); Bonanad, S
Meeting Abstract. 2018
Towarda more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).
Efficace, Fabio; (...); Zeidan, Amer M
Article. 10.1002/hem3.69. 2024
TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes
Bernard, Elsa; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2019-129392. 2019
TRANSCRIPTOMICAL ANALYSIS AND MODELING IN C.ELEGANS OF THE IDH2 R140 R172 MUTATION
Gonzalez-Romero, E.; (...); Cervera-Zamora, J., V
Meeting Abstract. 2019
Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.
Solves, Pilar; (...); Sanz, Jaime
Article. 10.3390/jcm12103467. 2023
Transfusion management in multiple myeloma patients receiving daratumumab: Experience of a single tertiary care centre.
Solves P; (...); Carpio N
Article. 10.1016/j.transci.2019.09.011. 2020
TRANSFUSIONAL REQUIREMENTS OF PATIENTS UNDERGOING TRANSPLANTATION OF HAEMATOPOIETIC PROGENITORS OF DIFFERENT SOURCES
Blanco, JA; (...); Alonso, MAS
Meeting Abstract. 2018
Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry
Diez-Campelo, Maria; (...); Valcarcel, David
Meeting Abstract. 10.1182/blood-2021-146019. 2021
UBA1 Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes
Sirenko, Maria; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2023-182949. 2023
Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors.
Article. 10.1038/s41409-020-0921-6. 2020
Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA
Borras, N; (...); Corrales, I
Article. 10.3324/haematol.2018.203166. 2019
Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.
Montesinos P; (...); Sanz MÁ
Article. 10.1007/s00277-019-03820-w. 2019
Update on Molecular Testing in von Willebrand Disease
Batlle, J; (...); PCM-EVW-ES Investigators Team
Review. 10.1055/s-0039-1679922. 2019
Upper-Body Exercises With External Resistance Are Well Tolerated and Enhance Muscle Activity in People With Hemophilia
Calatayud, J; (...); Casana, J
Article. 10.1093/ptj/pzy136. 2019
Usability and usefulness of a wearable activity tracker in patients with hemophilia
Querol-Fuentes, F; (...); Bonanad, S
Meeting Abstract. 2018
USE OF CRISPR/CAS9 TECHNOLOGY TO MODIFY THE IDH2 GENE IN BOTH IN-VIVO AND IN-VITRO MODELS
Gonzalez Romero, E.; (...); Cervera, J., V
Meeting Abstract. 2018
Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients
Rodriguez-Veiga, Rebeca; (...); Sanz, Miguel A.
Article. 10.1111/myc.12891. 2019
VALIDATION OF A PANEL OF GENES BY MASSIVE SEQUENCING FOR THE SCREENING OF GERMINAL MUTATIONS IN GENES ASSOCIATED WITH HEREDITARY MYELOID NEOPLASMS
Ibanez, M.; (...); Cervera, J., V
Meeting Abstract. 2019
VALIDATION OF PRECISION MEDICINE TEST FOR ACUTE MYELOID LEUKEMIA IN AN OBSERVATIONAL CLINICAL TRIAL
Montesinos, P; (...); Sanz, MA
Meeting Abstract. 2017
Validity of a depth camera for elbow range of motion measurement in haemophilic patients: The first step for a telemedicine approach
Mateo, F; (...); Querol-Fuentes, F
Meeting Abstract. 2018
Variation in the presentation pattern of primary biliary cholangitis (PBC) in Spain according to the diagnostic period: data from the Spanish registry of cholestatic and autoimmune liver diseases (COLHAI)
Rodriguez-Tajes, Sergio; (...); Carlota Londono, Maria
Meeting Abstract. 2023
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy
Mugoni, V; (...); Pandolfi, PP
Article. 10.1038/s41422-019-0162-7. 2019
WHAT IS THE OUTCOME OF PATIENTS IN THE INTERMEDIATE IPSS-R SCORE GROUP? SPANISH APPROACH FOR BETTER STRATIFICATION WITH CLASSICAL TOOLS
Guijo, AMR; (...); Diez-Campelo, M
Meeting Abstract. 10.1016/S0145-2126(17)30374-0. 2017
Campos de Estudio
Cita
HARMONY. HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY. (116026). COMISION EUROPEA. 2017-2023. IP:GUILLERMO SANZ SANTILLANA.